Qiagen shares surged after Bloomberg reported the company is working with advisers and has held talks with potential suitors about a possible sale. The report cited unnamed people with knowledge of the matter and noted the board has received interest amid CEO Thierry Bernard’s announced departure and recent transactions such as the Parse Biosciences acquisition. Analysts flagged strategic fits with larger life‑science tools companies and private equity; JP Morgan highlighted Agilent and Danaher as plausible suitors. The move follows improved diagnostics market conditions and has drawn investor attention to consolidation opportunities in molecular testing.